This commentary addresses our perspectives from a regulatory standpoint, as well as some controversies related to the use of neoadjuvant therapy as a platform for drug development.
|Original language||English (US)|
|Journal||ONCOLOGY (United States)|
|State||Published - Nov 15 2015|
ASJC Scopus subject areas
- Cancer Research